CA2376121C - Solution de xylometazoline et d'oxymetazoline stable - Google Patents

Solution de xylometazoline et d'oxymetazoline stable Download PDF

Info

Publication number
CA2376121C
CA2376121C CA002376121A CA2376121A CA2376121C CA 2376121 C CA2376121 C CA 2376121C CA 002376121 A CA002376121 A CA 002376121A CA 2376121 A CA2376121 A CA 2376121A CA 2376121 C CA2376121 C CA 2376121C
Authority
CA
Canada
Prior art keywords
formulation according
formulation
weight
buffer
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002376121A
Other languages
English (en)
Other versions
CA2376121A1 (fr
Inventor
Frieder Ulrich Maerz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23322017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2376121(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA2376121A1 publication Critical patent/CA2376121A1/fr
Application granted granted Critical
Publication of CA2376121C publication Critical patent/CA2376121C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

La présente invention concerne une solution de xylométazoline et/ou d'oxymétazoline biologiquement et chimiquement stable, comprenant, comme adjuvants, du glycérol et/ou du sorbitol.
CA002376121A 1999-06-22 2000-06-17 Solution de xylometazoline et d'oxymetazoline stable Expired - Fee Related CA2376121C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33778999A 1999-06-22 1999-06-22
US09/337,789 1999-06-22
PCT/EP2000/005583 WO2000078297A2 (fr) 1999-06-22 2000-06-17 Solution de xylometazoline et d'oxymetazoline stable

Publications (2)

Publication Number Publication Date
CA2376121A1 CA2376121A1 (fr) 2000-12-28
CA2376121C true CA2376121C (fr) 2008-06-10

Family

ID=23322017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002376121A Expired - Fee Related CA2376121C (fr) 1999-06-22 2000-06-17 Solution de xylometazoline et d'oxymetazoline stable

Country Status (22)

Country Link
US (2) US20040191177A1 (fr)
EP (1) EP1194145B1 (fr)
JP (1) JP2003502361A (fr)
KR (1) KR20020012001A (fr)
CN (1) CN1164271C (fr)
AT (1) ATE232099T1 (fr)
AU (1) AU765736B2 (fr)
BR (1) BR0011950A (fr)
CA (1) CA2376121C (fr)
CZ (1) CZ295595B6 (fr)
DE (1) DE50001217D1 (fr)
EA (1) EA003329B1 (fr)
ES (1) ES2188563T3 (fr)
HK (1) HK1045945B (fr)
HU (1) HUP0201700A3 (fr)
IL (1) IL147023A0 (fr)
MX (1) MXPA01012912A (fr)
PL (1) PL197542B1 (fr)
PT (1) PT1194145E (fr)
TR (1) TR200103694T2 (fr)
WO (1) WO2000078297A2 (fr)
ZA (1) ZA200110386B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60209511T2 (de) 2001-09-18 2006-10-05 Nycomed Danmark Aps Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
AU2003278962B2 (en) * 2002-06-20 2006-11-23 Novartis Consumer Health S.A. Nasal compositions comprising a mucopolysaccharide and propylene glycol
AU2003272517A1 (en) * 2002-09-13 2004-04-30 Zicam, Llc. Compositions to reduce congestion and methods for application thereof to the nasal membrane
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
EP2015733A2 (fr) * 2006-04-26 2009-01-21 Aciex, Inc. Compositions pour le traitement et la prévention du gonflement des paupières
US20090136598A1 (en) * 2006-04-26 2009-05-28 Aciex, Inc. Compositions for the Treatment and Prevention of Eyelid Swelling
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US20170348230A1 (en) 2014-12-24 2017-12-07 Jadran-Galenski Laboratorij D.D A nasal composition containing sea water as stability-improving excipient
EP4404916A1 (fr) 2021-09-22 2024-07-31 JADRAN - GALENSKI LABORATORIJ d.d. Composition pharmaceutique améliorée pour utilisation nasale, préparation et utilisation de celle-ci

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603131A (en) * 1982-04-26 1986-07-29 Bernstein Joel E Method and composition for treating and preventing irritation of the mucous membranes of the nose
US4970240A (en) * 1989-10-18 1990-11-13 Schering Corporation Fruity flavored nasal decongestant composition
US5114979A (en) * 1989-10-18 1992-05-19 Schering Corporation Fruity flavored nasal decongestant composition
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
DE19549421C2 (de) * 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
ES2190477T3 (es) * 1995-11-17 2003-08-01 Ursatec Verpackung Gmbh Dispensador de fluidos diseñado para proteger el contenido de la contaminacion.
DE19542959C1 (de) * 1995-11-17 1996-10-24 Ursatec Verpackung Gmbh Vor Kontamination schützende Abgabevorrichtung für Fluide
CA2311530C (fr) * 1998-01-30 2008-06-10 Novartis Consumer Health S.A. Preparations pharmaceutiques

Also Published As

Publication number Publication date
KR20020012001A (ko) 2002-02-09
ES2188563T3 (es) 2003-07-01
EA200200042A1 (ru) 2002-06-27
HK1045945B (zh) 2005-01-28
BR0011950A (pt) 2002-03-12
HUP0201700A2 (hu) 2002-12-28
WO2000078297A3 (fr) 2001-03-01
HK1045945A1 (en) 2002-12-20
HUP0201700A3 (en) 2003-02-28
MXPA01012912A (es) 2002-09-18
IL147023A0 (en) 2002-08-14
WO2000078297A2 (fr) 2000-12-28
AU765736B2 (en) 2003-09-25
US20040191177A1 (en) 2004-09-30
US20080011293A1 (en) 2008-01-17
CZ295595B6 (cs) 2005-08-17
JP2003502361A (ja) 2003-01-21
PT1194145E (pt) 2003-06-30
CA2376121A1 (fr) 2000-12-28
TR200103694T2 (tr) 2002-04-22
CZ20014568A3 (cs) 2002-03-13
PL352354A1 (en) 2003-08-11
EA003329B1 (ru) 2003-04-24
EP1194145A2 (fr) 2002-04-10
CN1164271C (zh) 2004-09-01
AU6150600A (en) 2001-01-09
EP1194145B1 (fr) 2003-02-05
DE50001217D1 (de) 2003-03-13
ATE232099T1 (de) 2003-02-15
ZA200110386B (en) 2003-04-22
CN1361689A (zh) 2002-07-31
PL197542B1 (pl) 2008-04-30

Similar Documents

Publication Publication Date Title
US20080011293A1 (en) Stable Xylometazoline and Oxymetazoline Solution
US5776919A (en) Potentiators of antimicrobial activity
US6492361B1 (en) Antibiotic compositions and methods for using same
US6548497B2 (en) Methods of reducing non-inflammatory pain
US8426474B2 (en) Antimicrobial wash and carrier solutions and uses thereof
US8956663B2 (en) Compositions and methods for treating vaginal infections and pathogenic vaginal biofilms
CN101578045A (zh) 抗微生物组合物
CN106572662A (zh) 抗微生物‑抗生物膜组合物及其作为个人护理产品的使用方法
US11331289B2 (en) Antimicrobial composition
KR20100017153A (ko) 균막 형성을 처리하기 위한 트리아졸 화합물
CN105126107A (zh) 一种液体伤口敷料
KR20080039342A (ko) 안과용 방부 조성물
US20180153840A1 (en) The compositions of glycerol and /or non-toxic amino acids for inhibiting and destroying biofilm, including related methods
KR0143509B1 (ko) 안국소용 조성물
JPH0748262A (ja) 外眼部投与用組成物
US5336508A (en) Preservative for pharmaceutical products
KR20190022542A (ko) 이식 후 감염의 예방 또는 치료를 위한 적어도 하나의 효소 및 적어도 하나의 살균 분자를 포함하는 조성물

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed